Moderate to Severe Asthma: News
- ATS 2022 NAVIGATOR Steers Uncontrolled Asthma Toward Calmer Seas
- Albuterol-Budesonide Combo Offers Better Rescue Therapy for Moderate to Severe Asthma
- More Evidence Links Asthma Severity to Age of Onset
- Gaps in Follow-Up Put Kids With Asthma at Risk of Recurrence
- Biologic Reduces Corticosteroid Use in Severe Asthma
- Dealing With Life-Threatening Asthma Attacks
- AAAAI 2022 Asthma: Easy Strategy Reduces Exacerbations, Improves Control
- Alert FDA Approves First-in-Class Drug for Severe Asthma
- Early Diagnosis of Bronchiectasis Critical in T2 Severe Asthma
- Dupilumab Cuts Severe Asthma Exacerbations in Children
- Poorly Controlled Asthma Predicts COVID-19 Hospitalization in Kids
- ACR 2021 Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis
- SLIT Safe for Asthma, but Efficacy Data Are Lacking
- Placebo Beat Risankizumab in Adults With Severe Asthma
- Itepekimab Reduces Loss of Asthma Control
- CHEST 2021 Dupilumab-Improved Lung Function Lasts in Children With Asthma
- Tree Nut Storage Proteins Best for Predicting Allergy
- EAACI 2021 Tezepelumab Reduces Asthma Exacerbation Rates by 56%
- EAACI 2021 Short-Acting Beta Agonist Overuse 'a Global Public Health Issue'
- EAACI 2021 Dupilumab Safe, Effective in Kids With Moderate-to-Severe Asthma